{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:35:45Z","timestamp":1757702145696},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.clinthera.2005.05.008","type":"journal-article","created":{"date-parts":[[2005,6,23]],"date-time":"2005-06-23T11:21:43Z","timestamp":1119525703000},"page":"511-530","source":"Crossref","is-referenced-by-count":21,"title":["Trospium chloride for the treatment of overactive bladder with urge incontinence"],"prefix":"10.1016","volume":"27","author":[{"given":"Devada","family":"Singh-Franco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caridad","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sony","family":"Tuteja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Zapantis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.05.008_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardization of terminology of lower urinary tract function: Report from the Standardization Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 6A","key":"10.1016\/j.clinthera.2005.05.008_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0090-4295(97)00587-6","article-title":"A neurologic basis for the overactive bladder","volume":"50","author":"de Groat","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2005.05.008_bib4","series-title":"Incontinence","first-page":"12","article-title":"Structure and function in continence and incontinence","author":"Flynn","year":"1999"},{"key":"10.1016\/j.clinthera.2005.05.008_bib5","series-title":"Urinary Incontinence","first-page":"7","article-title":"Anatomy and physiology","author":"Shah","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_bib6","series-title":"Conservative Treatment of Male Urinary Incontinence and Erectile Dysfunction","first-page":"21","article-title":"Urinary continence","author":"Dorey","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_bib7","series-title":"Pharmacotherapy, A Pathophysiologic Approach","first-page":"1543","article-title":"Urinary incontinence","author":"Rovner","year":"2002"},{"key":"10.1016\/j.clinthera.2005.05.008_bib8","series-title":"Pharmacotherapy. A Pathophysiologic Approach","first-page":"1533","article-title":"Management of benign prostatic hyperplasia","author":"Lee","year":"2002"},{"key":"10.1016\/j.clinthera.2005.05.008_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.urology.2003.10.037","article-title":"Costs of urinary incontinence and overactive bladder in the United States: A comparative study","volume":"63","author":"Hu","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2005.05.008_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.AOG.0000133482.20685.d1","article-title":"Urinary incontinence in elderly women: Findings from the Health, Aging, and Body Composition Study","volume":"104","author":"Jackson","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1464-410X.2003.04609.x","article-title":"The prevalence of urinary incontinence in women in four European countries","volume":"93","author":"Hunskaar","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2005.05.008_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1532-5415.1998.tb02469.x","article-title":"Variation in estimates of urinary incontinence prevalence in the community: Effects of differences in definition, population characteristics, and study type","volume":"46","author":"Thom","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2005.05.008_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1067\/mob.2002.124839","article-title":"Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status in women with urinary incontinence","volume":"187","author":"Melville","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0090-4295(00)00643-9","article-title":"Prevalence of urinary incontinence among institutionalized patients: A cross-sectional epidemiologic study in a midsized city in northern Italy","volume":"56","author":"Aggazzotti","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2005.05.008_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2005.05.008_sbref160","series-title":"AHFS Drug Information","first-page":"1180","article-title":"Propantheline bromide","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_sbref170","series-title":"AHFS Drug Information","first-page":"1206","article-title":"Propantheline bromide","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_bib17","series-title":"AHFS Drug Information","first-page":"1207","article-title":"Scopolamine hydrobromide","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_sbref190","series-title":"AHFS Drug Information","first-page":"2125","article-title":"Imipramine hydrochloride","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_sbref200","series-title":"AHFS Drug Information","first-page":"2147","article-title":"Imipramine hydrochloride","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_sbref210","series-title":"AHFS Drug Information","first-page":"2125","article-title":"Doxepine hydrochloride","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_sbref220","series-title":"AHFS Drug Information","first-page":"2146","article-title":"Doxepine hydrochloride","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_bib20","unstructured":"Ditropan [package insert]. Palo Alto, Calif: ALZA Corporation; 1999."},{"key":"10.1016\/j.clinthera.2005.05.008_bib21","unstructured":"Ditropan XL [package insert]. Mountain View, Calif: ALZA Corporation; 2004."},{"key":"10.1016\/j.clinthera.2005.05.008_bib22","unstructured":"Oxytrol [package insert]. Corona, Calif: Watson Laboratories; 2003."},{"key":"10.1016\/j.clinthera.2005.05.008_bib23","unstructured":"Detrol [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn; 1998."},{"key":"10.1016\/j.clinthera.2005.05.008_bib24","unstructured":"Detrol LA [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn; 2004."},{"key":"10.1016\/j.clinthera.2005.05.008_bib25","unstructured":"Sanctura [package insert]. Troisdorf, Germany: Madaus AG; 2004."},{"key":"10.1016\/j.clinthera.2005.05.008_bib32","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","article-title":"Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized controlled trial","volume":"165","author":"Malone-Lee","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib33","first-page":"687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial","volume":"78","author":"Diokno","year":"2003"},{"key":"10.1016\/j.clinthera.2005.05.008_bib34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2005.05.008_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0939-6411(97)00050-7","article-title":"Intestinal absorption of the quaternary trospium chloride: Permeability-lowering factors and bioavailabilities from oral dosage forms","volume":"43","author":"Langguth","year":"1997","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.clinthera.2005.05.008_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5414\/CPP42543","article-title":"Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration","volume":"42","author":"Schr\u00f6der","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.05.008_bib37","first-page":"R175","article-title":"Pharmacokinetics of single- and multiple-dose trospium chloride in elderly volunteers using a replicative design","volume":"357","author":"Zerres","year":"1998","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib38","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00191165","article-title":"Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers","volume":"47","author":"Pietzko","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11934-003-0023-1","article-title":"Trospium chloride: A quaternary amine with unique pharmacologic properties","volume":"4","author":"Pak","year":"2003","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.clinthera.2005.05.008_bib41","first-page":"456","article-title":"Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder","volume":"50","author":"Uckert","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2005.05.008_bib42","first-page":"984","article-title":"Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data","volume":"36","author":"Schladitz-Keil","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2005.05.008_bib43","series-title":"Program and abstracts of the Annual Meeting of the International Continence Society","article-title":"The effect of hepatic disease on the pharmacokinetics of trospium chloride","author":"Sandage","year":"2004"},{"key":"10.1016\/j.clinthera.2005.05.008_bib44","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2165\/00003088-200342140-00004","article-title":"Clinical pharmacokinetics of drugs used to treat urge incontinence","volume":"42","author":"Guay","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2005.05.008_bib45","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2165\/00003495-200464210-00005","article-title":"Trospium chloride in the management of overactive bladder","volume":"64","author":"Rovner","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2005.05.008_bib46","series-title":"Applied Clinical Pharmacokinetics","first-page":"3","article-title":"Clinical pharmacokinetic and pharmacodynamic concepts","author":"Bauer","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_bib47","series-title":"Applied Clinical Pharmacokinetics","first-page":"26","article-title":"Clinical pharmacokinetic equations and calculations","author":"Bauer","year":"2001"},{"key":"10.1016\/j.clinthera.2005.05.008_bib48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0773.1999.tb02026.x","article-title":"Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes","volume":"85","author":"Beckmann-Knopp","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib49","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000282207","article-title":"Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial","volume":"47","author":"St\u00f6hrer","year":"1991","journal-title":"Urol Int"},{"key":"10.1016\/j.clinthera.2005.05.008_bib50","first-page":"27","article-title":"Trospium chloride (Spasmo-lyt\u00ae) in patients with motor urge syndrome (detrusor instability): Double-blind, randomized, placebo-controlled study","volume":"2","author":"Alloussi","year":"1999","journal-title":"J Drug Assess"},{"key":"10.1016\/j.clinthera.2005.05.008_bib51","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1464-410x.2000.00575.x","article-title":"Efficacy of trospium chloride in patients with detrusor instability: A placebo-controlled, randomized, double-blind, multicentre clinical trial","volume":"85","author":"Cardozo","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2005.05.008_bib52","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","article-title":"Trospium chloride improves overactive bladder symptoms: A multicenter Phase III trial","volume":"171","author":"Zinner","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib53","series-title":"Program and abstracts of the Annual Meeting of the International Continence Society","article-title":"Psychometric validation of an urgency severity scale (IUSS) for patients with overactive bladder","author":"Bowden","year":"2003"},{"key":"10.1016\/j.clinthera.2005.05.008_bib54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF00451721","article-title":"Health-related quality of life measures for women with urinary incontinence: The Incontinence Impact Questionnaire and the Urogenital Distress Inventory","volume":"3","author":"Shumaker","year":"1994","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2005.05.008_bib55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","article-title":"Trospium chloride versus oxybutynin: A randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia","volume":"75","author":"Madersbacher","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.clinthera.2005.05.008_bib57","first-page":"85B","article-title":"Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge syndrome: A double-blind, placebo-controlled, multicenter clinical trial","volume":"19","author":"Junemann","year":"2000","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.clinthera.2005.05.008_bib58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5414\/CPP40295","article-title":"Trospium chloride in patients with detrusor overactivity: Meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily","volume":"40","author":"Frohlich","year":"2002","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T22:36:01Z","timestamp":1586298961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805000846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0149291805000846"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.05.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}